ALK-1

ALK-1 Molekülinformation

Englischer Name	Activin receptor-like kinase 1	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1	Target-Alias	EC:2.7.11.30，ACVRLK1，Activin A Receptor Type II-Like 1，Activin A Receptor， Type II-Like Kinase 1，EC 2.7.11，ALK-1，Serine/threonine-protein kinase receptor R3，TGF-B superfamily receptor type I，Activin receptor-like kinase 1，SKR3，ALK1，ACVRL1，Activin A Receptor Like Type 1，Activin A Receptor Type IL，TSR-I，EC 2.7.11.30，HHT2，ORW2，HHT
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Englischer Name	Activin receptor-like kinase 1
Target-Alias	EC:2.7.11.30，ACVRLK1，Activin A Receptor Type II-Like 1，Activin A Receptor， Type II-Like Kinase 1，EC 2.7.11，ALK-1，Serine/threonine-protein kinase receptor R3，TGF-B superfamily receptor type I，Activin receptor-like kinase 1，SKR3，ALK1，ACVRL1，Activin A Receptor Like Type 1，Activin A Receptor Type IL，TSR-I，EC 2.7.11.30，HHT2，ORW2，HHT
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

ALK-1 Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
His Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
AL1-H5228	Human	HEK293	Human ALK-1 / ACVRL1 Protein, His Tag, low endotoxin (MALS verified)				In den Warenkorb legen

Gesamtmenge1

ALK-1 Molekülhintergrund

Serine/threonine-protein kinase receptor R3 is an enzyme that in humans is encoded by the ALK1 gene. ALK1 is a receptor in the TGF beta signaling pathway. ALK1 protein is a receptor in the TGF beta signaling pathway. It plays an important role in vascular development, remodeling, and pathologic angiogenesis, play a role in stabilizing angiogenic vessels and contribute to resistance to anti-VEGF therapies, ALK1 blockade may represent an effective therapeutic opportunity complementary to the current antiangiogenic modalities in the clinic. Recently, researcher found that, ALK1-Fc inhibited BMP9-mediated Id-1 expression in human umbilical vein endothelial cells and inhibited cord formation by these cells on a Matrigel substrate, in a chick chorioallantoic membrane assay, ALK1-Fc reduced vascular endothelial growth factor-, fibroblast growth factor-, and BMP10-mediated vessel formation, and ALK1-Fc treatment reduced tumor burden in mice receiving orthotopic grafts of MCF7 mammary adenocarcinoma cells.

ALK-1 Molekülalias

ACVRL1,ACVRLK1,ALK-1,HHT,HHT2,ORW2,SKR3,TSR-I

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Ascrinvacumab	PF-3446962; GT-90001; PF-3-446-962; GT-90001C; ALK-1; GT90001C; PF-03446962	Phase 2 Clinical	Pfizer Inc	Carcinoma, Hepatocellular; Colorectal Neoplasms; Liver Neoplasms; Macular Degeneration; Mesothelioma; Neoplasms; Solid tumours	Details